AUTL logo

AUTOLUS THERAPEUTICS PLC

AUTLNASDAQ
πŸ† #2145 by market capEarnings Aug 11 Β· PreUS Equity
$2.33β–² $0.31 (+13.38%)
Live
1hβ€”
24hβ–² 13.4%
7dβ–² 19.5%
14dβ–² 61.8%
30dβ–² 43.8%
1yβ–Ό 5.5%
🏦Market Cap
$620M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+927.9%
High Growth
πŸ“ŠGross Margin
-11.2%
Thin
πŸ’΅FCF Margin
β€”
βš–οΈP/S Ratio
5.9x
Fair
Otter Score
64
Fair

Trading Snapshot

Day Range
$2.31 – $2.35
52-Week Range
$1.18 – $2.52
Volume
$2.35B
Avg Volume
$3.04B
Shares Outstanding
266.2M
Next Earnings
Sep 18, 2026

Fundamentals Snapshot

Annual Revenue
$93M
Last Q Revenue
$24M
P/E Ratio
β€”
P/S Ratio
5.9x
EPS (TTM)
$-1.09
Dividend Yield
β€”

Why Investors Own AUTL

  • βœ“High-growth profile β€” revenue up +21.0% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 49% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$93Mβ–² +17.8% YoY
Gross Margin (TTM)
49.4%β–² +3.7% YoY
Operating Income (TTM)
$13Mβ–² +17.8% YoY
Free Cash Flow (TTM)
$19Mβ–² +17.8% YoY

About AUTOLUS THERAPEUTICS PLC

A company profile for AUTOLUS THERAPEUTICS PLC isn’t available yet β€” check back soon.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$3.07
β–² +31.6% Upside
High Target$3.46
Low Target$2.45
Based on 31 analysts

Latest News & Updates